A retrospective study of Ceftolozane/Tazobactam against multi drug resistant Pseudomonas aeruginosa infections and extended-spectrum β-lactamase (ESBL)-producing strains: first outpatient clinical experience.

Trial Profile

A retrospective study of Ceftolozane/Tazobactam against multi drug resistant Pseudomonas aeruginosa infections and extended-spectrum β-lactamase (ESBL)-producing strains: first outpatient clinical experience.

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Dec 2016

At a glance

  • Drugs Ceftolozane/tazobactam (Primary)
  • Indications Gram-negative infections; Intra-abdominal infections; Respiratory tract infections; Skin and soft tissue infections; Urinary tract infections
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 28 Dec 2016 New trial record
    • 30 Oct 2016 Results presented at the IDWeek 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top